Related references
Note: Only part of the references are listed.Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma
Ian W. Flinn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
Kensei Tobinai et al.
ADVANCES IN THERAPY (2017)
Recommendations for Clinical Trial Development in Follicular Lymphoma
Kami Maddocks et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial
Tadeusz Robak et al.
LEUKEMIA & LYMPHOMA (2017)
Recommendations for Clinical Trial Development in Follicular Lymphoma
Kami Maddocks et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
The use of ofatumumab in the treatment of B-cell malignancies
Zar Ni Soe et al.
FUTURE ONCOLOGY (2017)
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Andrew D. Zelenetz et al.
LANCET ONCOLOGY (2017)
Role of stem cell transplant in lymphoma in the era of new drugs
Katerina Benekou et al.
CURRENT OPINION IN ONCOLOGY (2017)
Pros and cons of rituximab maintenance in follicular lymphoma
Lu Zhang et al.
CANCER TREATMENT REVIEWS (2017)
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling et al.
ANNALS OF ONCOLOGY (2016)
Introduction to a review series: the paradox of indolent B-cell lymphoma
Laurie H. Sehn
BLOOD (2016)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Emerging therapies for the treatment of relapsed or refractory follicular lymphoma
D. MacDonald et al.
CURRENT ONCOLOGY (2016)
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
Mathias Rummel et al.
LANCET ONCOLOGY (2016)
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
Laurie H. Sehn et al.
LANCET ONCOLOGY (2016)
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
Peter Hillmen et al.
LANCET (2015)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
Myron S. Czuczman et al.
BLOOD (2012)
Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma
Matthew J. Barth et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
Nishant Tageja
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2011)
Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma Results From a Multicenter Study
Brad S. Kahl et al.
CANCER (2010)
Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
Marinus H. J. van Oers et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
Anton Hagenbeek et al.
BLOOD (2008)
Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody
Wim K. Bleeker et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study
Jonathan W. Friedberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma
Bridgette Collins-Burow et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
Jessica L. Teeling et al.
JOURNAL OF IMMUNOLOGY (2006)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma
MJ Rummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma
MS Czuczman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly X 4 schedule
M Ghielmini et al.
BLOOD (2004)
Monoclonal antibodies in the treatment of cancer, part 1
RJ Cersosimo
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2003)
Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma
JD Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
